reveal novel mechanisms of kallistatin
in protection against senescence, aging, and cancer by modulating miR-34a and miR-21 levels and inhibiting oxidative stress.
Kallistatin was first identified in human plasma as a tissue kallikrein inhibitor and a serine proteinase inhibitor [20-23].
Kallistatin Inhibits Oxidative Stress and Inflammation
Reduced kallistatin levels are correlated with increased oxidative stress, inflammation, and organ damage in animal models of hypertension, cardiovascular, and renal damage [22, 35, 40, 42].
Kallistatin is an antioxidant as its heparin-binding site is essential for blocking TNF-[alpha]-induced NADPH oxidase activity and expression in endothelial cells [33, 42].
Kallistatin was first identified in human plasma as a tissue kallikrein-binding protein (KBP) and characterized as a serine proteinase inhibitor (serpin) [1-3].
Kallistatin belongs to the serpin family, which includes a1-antitrypsin and a1-antichymotrypsin .
Reduced Circulating Kallistatin Levels Are Inversely Associated with Oxidative Stress